NovoCure (NVCR) Property, Plant & Equipment (Net) Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 13.22% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.93% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 8.89% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 19.89% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 7.35% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 14.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 8.56% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 10.46% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -4.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.17% |
| Dec 31, 2025 | -0.07% |
| Sep 30, 2025 | 9.18% |
| Jun 30, 2025 | 20.84% |
| Mar 31, 2025 | 35.10% |
| Dec 31, 2024 | 50.86% |
| Sep 30, 2024 | 60.77% |
| Jun 30, 2024 | 61.52% |
| Mar 31, 2024 | 61.62% |
| Dec 31, 2023 | 57.53% |
| Sep 30, 2023 | 53.18% |
| Jun 30, 2023 | 54.95% |
| Mar 31, 2023 | 45.40% |
| Dec 31, 2022 | 44.00% |
| Sep 30, 2022 | 154.25% |
| Jun 30, 2022 | 124.01% |
| Mar 31, 2022 | 113.69% |
| Dec 31, 2021 | 99.15% |
| Sep 30, 2021 | 13.90% |
| Jun 30, 2021 | 12.60% |
| Mar 31, 2021 | 19.99% |
| Dec 31, 2020 | 21.98% |
| Sep 30, 2020 | 21.91% |
| Jun 30, 2020 | 25.37% |
| Mar 31, 2020 | 16.11% |
| Dec 31, 2019 | 10.66% |
| Sep 30, 2019 | -1.62% |
| Jun 30, 2019 | -5.53% |
| Mar 31, 2019 | -5.40% |
| Dec 31, 2018 | -6.52% |
| Sep 30, 2018 | -8.51% |
| Jun 30, 2018 | -7.59% |
| Mar 31, 2018 | -11.33% |
| Dec 31, 2017 | -7.96% |
| Sep 30, 2017 | -5.31% |
| Jun 30, 2017 | 9.17% |
| Mar 31, 2017 | 41.59% |
| Dec 31, 2016 | 49.76% |
| Sep 30, 2016 | 61.91% |
| Dec 31, 2015 | 75.56% |